Testing if the drug ulixertinib can reach brain tumors
Original title: Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Gliomas
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a very early test in people, looking at whether the drug even reaches the brain.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study checks whether a drug called ulixertinib can get into the brain in people whose brain tumor has come back.
Who this trial is for. This trial is for people with a brain tumor that has come back. It tests a drug called ulixertinib. The goal is to learn if the drug can cross the blood-brain barrier, the natural shield around the brain.
Where it stands. There are no results yet. The trial is measuring whether the drug can get past that shield and reach the brain. The answer is not in yet. This trial has not reported results.
What this means, and what it doesn't
What it could mean: If the drug can reach the brain, that would be a first step toward testing if it helps. Nothing is known yet about whether it works. Someone who fits this picture could ask their care team about it.
What it doesn't mean: This does not mean ulixertinib is a treatment you can get. A trial is a test, not proven care. Joining a trial is not a promise that it will help you. It is not a cure.
Source: ClinicalTrials.gov, November 2, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.